ncRNA basic information ncRNA ID: MIMAT0000459 ncRNA Database: miRBase ncRNA Name: miR-193a-3p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: SRSF2 ncRNA Pathway: the mitochondrial pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: The purpose of the present study was to examine the mechanism of miRNA-mediated chemoresistance to cisplatin in CD44-positive gastric cancer stem cells. We sorted gastric cancer cells according to level of CD44 expression by FACS and analyzed their miRNA expression profiles by microarray analysis. We found that miR-193a-3p was significantly upregulated in CD44(+) cells compared with CD44(-) cells. Moreover, SRSF2 of miR-193a-3p target gene was downregulated in CD44(+) cells. We studied the modulation of Bcl-X and caspase 9 mRNA splicing by SRSF2 and found that more pro-apoptotic variants of these genes were generated. We also found that downstream anti-apoptotic genes such as Bcl-2 were upregulated, whereas pro-apoptotic genes such as Bax and cytochrome C were downregulated in CD44(+) cells compared to CD44(-) cells. In addition, we found that an elevated level of miR-193a-3p triggered the development of cisplatin resistance in CD44(+) cells. Inhibition of miR-193a-3p in CD44(+) cells increased SRSF2 expression and also altered the levels of multiple apoptotic genes. Furthermore, inhibition of miR-193a-3p reduced cell viability and increased the number of apoptotic cells. Therefore, miR-193a-3p may be implicated in the development of cisplatin resistance through regulation of the mitochondrial apoptosis pathway. Drug Response: resistant

Cancer basic information Cancer: stomach cancer Tissue/Cell: cell line (MKN45,AGS,KATO III)

Other information Title: Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Journal: Cancer Sci Published: 2019 PubMed ID: 30485589